Allogene Therapeutics
$18.899876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$18.89
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.21 (-1.10%) Today
$0.00 (0.00%) As of 8:00 PM EDT after-hours
Why Robinhood?
You can buy or sell ALLO and other stocks, options, ETFs, and crypto commission-free!
About ALLO
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Read More Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.
Employees
206
Headquarters
South San Francisco, California
Founded
2017
Market Cap
2.36B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
627.53K
High Today
$19.90
Low Today
$18.71
Open Price
$19.02
Volume
473.09K
52 Week High
$33.80
52 Week Low
$17.43
Collections
Analyst Ratings
69%
of 16 ratings
Buy
69%
Hold
31%
Sell
0%
ALLO Earnings
-$10.71
-$7.14
-$3.57
$0.00
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Estimated
— per share
Actual
Expected May 7, Pre-Market